The PARP Inhibitor Veliparib Can Be Safely Added to Bendamustine and Rituximab and Has Preliminary Evidence of Activity in B-Cell Lymphoma

The PARP inhibitor veliparib enhances the cytotoxicity of alkylating agents. This phase I study evaluated veliparib with the bifunctional alkylator bendamustine (VB) in patients with relapsed/refractory lymphoma, multiple myeloma, and solid malignancies, with a cohort expansion of VB with rituximab...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical cancer research 2017-08, Vol.23 (15), p.4119-4126
Hauptverfasser:	Soumerai, Jacob D, Zelenetz, Andrew D, Moskowitz, Craig H, Palomba, M Lia, Hamlin, Jr, Paul A, Noy, Ariela, Straus, David J, Moskowitz, Alison J, Younes, Anas, Matasar, Matthew J, Horwitz, Steven M, Portlock, Carol S, Konner, Jason A, Gounder, Mrinal M, Hyman, David M, Voss, Martin H, Fury, Matthew G, Gajria, Devika, Carvajal, Richard D, Ho, Alan L, Beumer, Jan H, Kiesel, Brian, Zhang, Zhigang, Chen, Alice, Little, Richard F, Jarjies, Christine, Dang, Thu O, France, Fallon, Mishra, Nishant, Gerecitano, John F
Format:	Artikel
Sprache:	eng
Schlagworte:	Alkylating agents Alkylation Anemia B-cell lymphoma Cancer Cytotoxicity Expansion Experimental design Hypertension Hypophosphatemia Immunotherapy Inhibitors Leukopenia Lymphocytes B Lymphoma Lymphopenia Monoclonal antibodies Multiple myeloma Nausea Neutropenia Patients Pharmacokinetics Pharmacology Poly(ADP-ribose) polymerase Quality Rituximab Targeted cancer therapy Thrombocytopenia Toxicity
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!